Traders should monitor first-day trading dynamics for IPO pop or fade; the size of the offering and strong investor interest may support near-term liquidity, but as a clinical-stage biotech with no commercial revenue, valuation will depend entirely on future trial outcomes and market appetite for obesity-related assets.
Price Chart
Executive Summary
Kailera Therapeutics priced its initial public offering of 39,062,500 shares at $16.00 per share, raising $625 million in gross proceeds before expenses. The company has also granted underwriters a 30-day option to purchase up to an additional 5,859,375 shares. Shares will begin trading on Nasdaq under 'KLRA' on April 17, 2026.
Key Financial Metrics
Key Facts
- Kailera Therapeutics priced its IPO at $16.00 per share.
- Total shares offered: 39,062,500, all by the company.
- Gross proceeds: $625 million, excluding underwriter option.
- Underwriters granted a 30-day option to purchase up to 5,859,375 additional shares.
- Stock to begin trading on Nasdaq on April 17, 2026, under ticker KLRA.
- Expected closing date: April 20, 2026, subject to customary conditions.
- Joint book-running managers: J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI; William Blair as lead manager.
Financial Impact
The company raised $625 million in gross proceeds from the IPO, with potential for an additional $93.75 million if the underwriters' option is fully exercised.
Risk Factors
- Dilution from the issuance of new shares.
- Volatility on debut due to IPO demand and lock-up dynamics.
- No revenue or profits yet—valuation is purely speculative based on pipeline potential.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275907 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access